Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden

BACKGROUND: Voriconazole is well established as standard treatment for invasive aspergillosis (IA). In 2017, isavuconazole, a new antifungal from the azole class, with a broader pathogen spectrum, was introduced in Sweden. A model has therefore been developed to compare the cost-effectiveness of isa...

Descripción completa

Detalles Bibliográficos
Autores principales: Floros, Lefteris, Kuessner, Daniel, Posthumus, Jan, Bagshaw, Emma, Sjölin, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371439/
https://www.ncbi.nlm.nih.gov/pubmed/30744563
http://dx.doi.org/10.1186/s12879-019-3683-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371439/
https://www.ncbi.nlm.nih.gov/pubmed/30744563
http://dx.doi.org/10.1186/s12879-019-3683-2

Ejemplares similares